A Population-based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia

Wen-Yue Liu, Li-You Lian, Huai Zhang, Sui-Dan Chen, Xin-Zhe Jin, Ni Zhang, Chen-Hui Ye, Wen-Ying Chen, George Goh Boon Bee, Fu-Di Wang, Luca Miele, Elena Corradini, Luca Valenti, Ming-Hua Zheng

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Context: There is limited data on the clinical significance of metabolic hyperferritinemia (MHF) based on the most recent consensus.Objective: We aimed to validate the clinical outcomes of MHF in the general population and patients with biopsy-proven metabolic dysfunction-associated fatty liver disease (MAFLD).Methods: The NHANES database and PERSONS cohort were included. MHF was defined as elevated serum ferritin with metabolic dysfunction (MD) and stratified into different grades according to ferritin (grade 1: 200 [females]/300 [males]-550 ng/mL; grade 2: 550-1000 ng/mL; grade 3: >1000 ng/mL). The clinical outcomes, including all-cause death, comorbidities, and liver histology, were compared between non-MHF and MHF in adjusted models.Results: In NHANES, compared with non-MHF with MD, MHF was related to higher risks of advanced fibrosis (P = .036), elevated albumin-creatinine ratio (UACR, P = .001), and sarcopenia (P = .013). Although the association between all grades of MHF and mortality was insignificant (P = .122), grades 2/3 was associated with increased mortality (P = .029). When comparing with non-MHF without MD, the harmful effects of MHF were more significant in mortality (P < .001), elevated UACR (P < .001), cardiovascular disease (P = .028), and sarcopenia (P < .001). In the PERSONS cohort, MHF was associated with more advanced grades of steatosis (P < .001), lobular inflammation (P < .001), advanced fibrosis (P = .017), and more severe hepatocellular iron deposition (P < .001).Conclusion: Both in the general population and in at-risk individuals with MAFLD, MHF was related with poorer clinical outcomes.
Lingua originaleEnglish
pagine (da-a)1540-1549
Numero di pagine10
RivistaTHE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
Volume109
DOI
Stato di pubblicazionePubblicato - 2024

Keywords

  • Iron overload
  • Metabolic dysfunction-associated fatty liver disease
  • Metabolic hyperferritinemia
  • Metabolic syndrome

Fingerprint

Entra nei temi di ricerca di 'A Population-based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia'. Insieme formano una fingerprint unica.

Cita questo